Vor, Abound Bio to develop multitargeted CAR T therapies

By The Science Advisory Board staff writers

June 11, 2021 -- Vor Biopharma has entered into a multiyear strategic collaboration and license agreement with Abound Bio to research both single- and multitargeted chimeric antigen receptor (CAR) T-cell treatments.

Under the terms of the agreement, the CAR T treatments will be used in combination with Vor's engineered hematopoietic stem cell platform, which shields the patient from unwanted side effects. The goal is to generate novel treatment systems for patients with acute myeloid leukemia and other forms of blood cancer, the companies said.

Financial terms of the deal were not disclosed.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.